))
BIOSECURE Act - The potential $3.6bn+ gap, Impact on Jobs and Skills shifts with Amber Tong, Senior Editor at EndPoint News
Manage episode 420577192 series 3557116
Content provided by Charles Spence. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Charles Spence or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode,Charles talks with Amber Tong, a senior editor at Endpoints News, about how the Biosecure Act could impact the biotech and pharma sectors.
Amber shares thoughts on how this law could change U.S.-China biopharma ties, jobs, and making medicines. We also look into how things are changing in this area, who might benefit or not, and the big global tensions that affect these shifts.
Here's what you are in for:
00:00 Introduction
00:33 Welcoming the Guest
02:36 Discussing the Biosecure Act
04:34 Impact on the Biotech Industry
07:17 Geopolitical Tensions and Historical Context
16:09 Potential Winners and Losers
35:16 Future Predictions and Conclusion
About Amber Tong
Amber Tong is a senior editor at Endpoints News, which is a global specialty publication covering the biotech and pharmaceutical industries. She's a reporter/editor with more than six years of experience covering the biopharma industry, with a particular focus on the growing role China plays on the global stage.
Amber is also at BIO San Diego 2024, go say hi.
Useful Information on BIOSECURE
Endpoints' latest articles:
BIO: China tensions, fixing gene therapy’s business model, and the stop-start market recovery
WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down
The US could upend biopharma manufacturing. WuXi rivals have an opening
https://endpts.com/the-us-could-upend-biopharma-manufacturing-wuxi-rivals-have-an-opening/
US-China tensions threaten to ensnare additional Chinese biopharma contractors
https://endpts.com/us-china-tensions-threaten-to-ensnare-additional-chinese-biopharma-contractors/
New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies
BIO CEO defends the organization's about-face on the Biosecure Act
https://endpts.com/bio-ceo-defends-the-organizations-about-face-on-the-biosecure-act/
Medicxi backs Chinese biotech's next-gen KRAS G12C drug with $40M injection
https://endpts.com/medicxi-backs-d3-bios-next-gen-kras-g12c-drug-with-40m-injection/
About Charles
Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.
He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.
Connect with Charles:
LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
Website: https://www.discera-search.com/
15 episodes
Share
